6 signals · bluesky, News / RSS
Scores are directional signals derived from aggregated public data — not verified findings or investment advice. Methodology
Signal-based estimates from public data — not verified assessments. Learn more
Some stress signals present but below significant thresholds.
Low risk signals — no significant operational or reputational pressure detected.
Relay Therapeutics exhibits low workplace stress and risk signals with modest positive market sentiment from analyst actions.
Current workplace stress and risk metrics for Relay Therapeutics remain low, though confidence in these signals is limited. Analyst actions, including price target adjustments and trading volume increases, suggest moderate positive sentiment toward the company's prospects.
Relay Therapeutics $RLAY Guggenheim Raises price target from 22.00 to 26.00. Maintains Buy. https://fundspec.io Don't just watch RLAY move, predict it! Build your own custom AI trading models for RLAY today by downloading the FundSpec App on the AppStore or PlayStore!
Relay Therapeutics $RLAY Guggenheim Raises price target from 22.00 to 26.00.
Relay Therapeutics (NASDAQ:RLAY) Sees Unusually-High Trading Volume on Analyst Upgrade Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) shares saw strong trading volume on Thursday after ... #Banking #Price #Articles Origin | Interest | Match
Relay Therapeutics (NASDAQ:RLAY) Sees Unusually-High Trading Volume on Analyst Upgrade Relay Therapeutics, Inc.
AI-driven structure-based drug discovery.
Based on 6 signals across 2 sources · snapshot 26 Jun 2026
Limited — treat this score as early-stage; more data needed.
Limited coverage — score may shift as signals arrive.
Based on 6 signals across 2 sources
Scores are directional signals derived from public data — not certified assessments or recommendations. Confidence indicates data coverage, not accuracy. Learn how scores are calculated →
Derived from public sources such as news, filings, and reported events.
What this means
Limited signals collected so far — this score may shift significantly as more data arrives.
AI-generated from public signals — may be incomplete. Based on 3 recent signals.
This summary is generated from publicly available review and signal data. It is intended as an indicative overview only and should not be used as the sole basis for employment, investment, or business decisions. Signal volume and source diversity may limit representativeness.
AI summaries are generated from public signals and may not reflect the full picture.
Relay Therapeutics (RLAY) Stock Rating Upgrade Based on Trial Data Relay Therapeutics (RLAY) received an upgrade in stock rating from Jones Trading following the release of new trial da… https://newsstocks.live/news/relay-therapeutics-rlay-stock-rating-upgrade-based-on-trial-data #Finance #Markets